2. Anti-infection
  3. HCV

HCV

HCV

Related Products

PDF 0.65 MB

Hepatitis C virus (HCV) is a positive-strand RNA virus grouped in the genus Hepacivirus within the family Flaviviridae. HCV is classified into at least 6 genotypes (gt), and its error-prone polymerase leads to more than 50 subtypes. The long open reading frame, which encodes the HCV polyprotein, is processed by host and viral proteases and gives rise to three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2) and seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). NS2 and p7 are essential for virus assembly but not RNA replication, whereas NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC). The NS3 protein is composed of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase), NS4A serves as a cofactor for NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is considered to play key roles in multiple steps of the HCV life cycle.NS5A inhibitors exhibit a rapid inhibition of virus infectivity shortly after administration to HCV-infected cells.

The HCV protein NS5A prevents the apoptosis-enabling loss of intracellular potassium by inhibiting Kv2.1 function and thus blocking hepatocyte cell death.

The HCV RNA-dependent RNA polymerase (RdRp) has long been a prime target for antiviral development because of its critical role in viral replication and the absence of a mammalian homologous enzyme.

The combination of lucidone and alpha interferon, the protease inhibitor Telaprevir, the NS5A inhibitor BMS-790052, or the NS5B polymerase inhibitor PSI-7977, synergistically suppresses HCV RNA replication.

HCV Related Products (328):

Cat. No. Product Name Effect Purity
  • HY-13740
    Resiquimod Inhibitor 99.95%
    Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
  • HY-N0003
    Honokiol Inhibitor 99.90%
    Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].
  • HY-107433
    U18666A Inhibitor
    U18666A, an intra-cellular cholesterol transport inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus[1].
  • HY-B0434
    Ribavirin Inhibitor
    Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.
  • HY-B0568
    Deferiprone Inhibitor
    Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study[1][2][3][4][5][6][7][8].
  • HY-171587
    3′-Deoxy CTP Inhibitor
    3′-Deoxy CTP is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of HCV nonstructural protein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs[1].
  • HY-171587A
    3′-Deoxy CTP trisodium Inhibitor
    3′-Deoxy CTP (trisodium) is the sodium salt form of 3′-Deoxy CTP (HY-171587). 3′-Deoxy CTP (trisodium) is a nucleotide analogue and a mandatory chain terminator. 3′-Deoxy CTP (trisodium) can cause chain termination by lacking the 3′-hydroxyl group, inhibiting the RNA synthesis activity of HCV nonstructural protein (NS5B) polymerase and blocking viral replication. 3′-Deoxy CTP (trisodium) can be used to study the chain termination mechanism of HCV polymerase and the development of antiviral drugs[1].
  • HY-10468R
    NM107 (Standard) Inhibitor
    NM107 (Standard) is the analytical standard of NM107. This product is intended for research and analytical applications. NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM[1][2].
  • HY-I0726
    Enantiomer of Sofosbuvir Control 99.68%
    Enantiomer of Sofosbuvir is an enantiomer of Sofosbuvir, a prescription medicine for the treatment of patients with chronic hepatitis C. There is no biological activity report on enantiomer of Sofosbuvir until now.
  • HY-123805
    KIN1400 Inhibitor
    KIN1400 is a potent IRF3 activator. KIN1400 triggers IRF3-dependent innate immune antiviral genes (RIG-I, MDA5, IFIT1, and Mx1) and IFN-β expression. KIN1400 inhibits WNV and DV, two mosquito-borne members of the Flaviviridae and the genus Flavivirus. KIN1400 also inhibits HCV replication. KIN1400 induces innate antiviral immunity through a MAVS-IRF3 axis[1].
  • HY-P10657
    Ac-DEMEEC-OH Inhibitor
    Ac-DEMEEC-OH is a HCV NS3 protease competitive inhibitor (Ki: 0.6 µM)[1].
  • HY-15602AS
    Ledipasvir-d6 hydrochloride Inhibitor
    Ledipasvir-d6 hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
  • HY-15236
    PSI-6206 Inhibitor 99.89%
    PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.
  • HY-12633
    GS-6620 Inhibitor 98.93%
    GS-6620 is potent and selective pangenotype HCV inhibitor against HCV replicons of genotypes 1 to 6 (EC50: 0.048 to 0.68 μM). GS-6620 shows limited activities against other viruses, maintaining only some of its activity against the closely related bovine viral diarrhea virus (EC50, 1.5 μM)[1].
  • HY-10468
    NM107 Inhibitor 99.23%
    NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM[1][2].
  • HY-100313A
    YM-53601 Inhibitor 99.37%
    YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo[1]. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent[2]. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation[3].
  • HY-10544
    Tegobuvir Inhibitor 98.01%
    Tegobuvir is a specific, covalent inhibitor of the HCV NS5B polymerase.
  • HY-159737
    Rociclovir Inhibitor
    Rociclovir (HOE 602) is an acyclic nucleoside derivative. Rociclovir protects mice against HSV and MCMV infections, but lacks antiviral activity in cell cultures[1].
  • HY-169112
    HCV-IN-46 Inhibitor
    HCV-IN-46 (compound 6d) is a HCV inhibitor with an EC50 value of 3.717 μM. HCV-IN-46 has antiviral activity[1].
  • HY-P4027
    HCV-1 e2 Protein (554-569) Inhibitor
    HCV-1 e2 Protein (554-569) is one of the main antigenic regions of HCV envelope 2 (e2) protein. The HCV-1 e2 Protein (554-569) contains a putative n-glycosylation site, which was previously thought to influence the immune recognition of e2[1].